Skip to main content
. Author manuscript; available in PMC: 2024 Jun 1.
Published in final edited form as: Clin Cancer Res. 2023 Dec 1;29(23):4930–4940. doi: 10.1158/1078-0432.CCR-23-1441

Figure 2. PI3Ki/MEKi combination therapy potently suppresses histone lactylation and enhances phagocytosis within activated TAM, relative to single agent controls.

Figure 2.

(A) Single cell suspensions of PTEN/p53-deficient prostate GEM tumors were treated with copanlisib (C, 100 nM), trametinib (T, 5 nM) or their combination for 24 hours, and conditioned media (CM) was collected at the end of treatment. FACS-sorted TAM were incubated ex vivo in CM for 24 hours, followed by co-culture with CTV dye stained-AC1/SC1 cells for 2 hours. Bar graphs demonstrate histone lactylation status (B) and phagocytic activity (C) of MHC-IIhi/PD-1hi/lo expressing TAM, relative to untreated group. FC = fold change. n=2 independent biological experiments. Significances/p-values were calculated by one-way ANOVA and indicated as follows, *p<0.05, **p<0.01 and ***p<0.001.